Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 76 - 100 of 3007 in total

Nedaplatin

Nedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.
Approved
Investigational

Calcium ascorbate

Approved
Nutraceutical
Matched Mixtures name: … Zinc With Vitamin C Lozenges ... C-1000 Plus Zinc & Potassium …

Alclometasone

Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.
Approved

Lisocabtagene maraleucel

Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel.[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard...
Approved
Matched Description: … [L31588] CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing ... [A228493] However, data on the efficacy of CAR T-cell therapies on less severe forms of B-cell lymphoma ... Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene …
Matched Categories: … CD19-Directed Genetically Modified Autologous T-cell Immunotherapies …

Lipegfilgrastim

Lipegfilgrastim, previously known as XM22, is a pegylated, recombinant granulocyte colony-stimulating factor (G-CSF) that was synthetized using a highly site-specific glycoPEGylation technology . It is used as an alternate to DB00019 for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropenia. Since July 2013, lipegfilgrastim...
Approved
Investigational
Matched Categories: … Hematopoietic Cell Growth Factors …

Ciltacabtagene autoleucel

Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000, and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience a range of symptoms including...
Approved
Investigational
Matched Description: … [A245854] B-cell maturation antigen (BCMA) is a transmembrane glycoprotein member of the tumor necrosis ... blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell ... Ciltacabtagene autoleucel (Carvykti, Jannsen Biotech Inc.) is a BCMA-directed genetically modified autologous T-cell …
Matched Categories: … Antineoplastic cell and gene therapy …

Amphetamine

Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first...
Approved
Illicit
Investigational

Aldesleukin

Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from...
Approved
Matched Categories: … Increased Lymphocyte Cell Production …

Betibeglogene autotemcel

Betibeglogene autotemcel is an autologous gene therapy that adds functional copies of the β-globin gene (βA-T87Q-globin) to hematopoietic stem cells in order to treat β-thalassemia. β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. This affects...
Approved
Investigational
Matched Description: … This affects hemoglobin levels, and in patients with severe forms of this disease, long-term red cell ... [A251770] Allogeneic hematopoietic-cell transplantation would be a therapeutic option in patients with …
Matched Categories: … Autologous Cultured Cell ... Autologous Hematopoietic Stem Cell-Based Gene Therapy …

Lovotibeglogene autotemcel

Lovotibeglogene autotemcel consists of autologous hematopoietic stem and progenitor cells transduced with the BB305 lentiviral vector encoding a modified β-globin gene. Specifically, lovotibeglogene autotemcel provides a functional copy of a modified beta-globin gene (βA-T87Q-globin) that when combined with α-globin, produces hemoglobins with similar oxygen-binding capacity as wild type hemoglobin. Additionally,...
Approved
Investigational
Matched Description: … lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell ... exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based …
Matched Categories: … Autologous Cultured Cell ... Autologous Hematopoietic Stem Cell-Based Gene Therapy …

Tafasitamab

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19...
Approved
Investigational
Matched Description: … made it a desirable target in the treatment these B-cell malignancies. ... Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell ... leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL))[L15302] has …
Matched Categories: … Lymphoma, B-Cell …

Cefapirin

Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.
Approved
Vet approved

Albiglutide

Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the...
Approved

Loncastuximab tesirine

Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. On April 23 2021, the Food and Drug Administration granted accelerated...
Approved
Investigational
Matched Description: … Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients ... therapy was developed by ADC Therapeutics and its accelerated approval for relapsed or refractory B-cell …

Glofitamab

Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.[L45698,A258488] Glofitamab was approved...
Approved
Investigational
Matched Description: … Canada in March 2023 for the treatment of certain patients with relapsed or refractory diffuse large B-cell ... for patients having failed other systemic therapies or for whom targeted therapies - such as CAR-T cell ... for the treatment of patients with relapsed or refractory DLBCL not otherwise specified or large B-cell …

Interferon alfa-2b

Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Approved

Azficel-T

Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. Dermal fibroblasts are collected from the post-auricular biopsy tissue and aseptically expanded using standard tissue-culture procedures until sufficient cells for three doses are obtained [FDA Label]....
Approved
Investigational
Matched Description: … Expanded cells are then suspended in a cell medium. …
Matched Categories: … Autologous Cultured Cell …

Cyanocobalamin

Cyanocobalamin (commonly known as Vitamin B12) is a highly complex, essential vitamin, owing its name to the fact that it contains the mineral, cobalt. This vitamin is produced naturally by bacteria , and is necessary for DNA synthesis and cellular energy production. Vitamin B12 has many forms, including the cyano-,...
Approved
Nutraceutical
Matched Mixtures name: … PEDIAVIT ZINC ... SURBEX ZINC FILMTAB ... Surbex-500 With Zinc …

Pralatrexate

Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma . Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts. Compared to methotrexate, pralatrexate has better accumulation in cancer cells. Pralatrexate is designed to have...
Approved
Investigational
Matched Description: … Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma ... L37674] It is also being studied for other types of lymphoma and solid malignancy such as non-small-cell …

Bortezomib

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells,...
Approved
Investigational
Matched Description: … dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell ... proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell …

Bleomycin

A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Approved
Investigational

Selenium Sulfide

Selenium Sulfide is an antifungal agent as well as a cytostatic agent, slowing the growth of hyperproliferative cells in seborrhea. Selenium Sulfide is the active ingredient often used in shampoos for the treatment of dandruff, seborrheic dermatitis and tinea capitis, a fungal infection that is primarily a disease of preadolescent...
Approved

Rifamycin

Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence...
Approved
Investigational

Pazopanib

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Approved

Teclistamab

Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds,[A253587, L43622] allowing the drug...
Approved
Investigational
Matched Description: … IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell ... , L43622] allowing the drug to recruit CD3-expressing T cells to BCMA-expressing cells to promote T cell–mediated …
Matched Categories: … Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager …
Displaying drugs 76 - 100 of 3007 in total